In vitro assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatment

2005 ◽  
Vol 16 (4) ◽  
pp. 417-422 ◽  
Author(s):  
Aur??lie Cabrespine ◽  
Jacques-Olivier Bay ◽  
Chantal Barthomeuf ◽  
Herv?? Cur?? ◽  
Philippe Chollet ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Treatment ◽  
Cytotoxic Agent ◽  
Hormone Refractory Prostate Cancer ◽  
Prostate Cancer Treatment ◽  
In Vitro Assessment ◽  
Hormone Refractory

Possible Benefits of Curcumin Regimen in Combination With Taxane Chemotherapy for Hormone-Refractory Prostate Cancer Treatment

2010 ◽  
Vol 62 (2) ◽  
pp. 148-153 ◽  
Author(s):  
Aurélie Cabrespine-Faugeras ◽  
Mathilde Bayet-Robert ◽  
Jacques-Olivier Bay ◽  
Philippe Chollet ◽  
Chantal Barthomeuf
Keyword(s):  
Prostate Cancer ◽  
Cancer Treatment ◽  
Hormone Refractory Prostate Cancer ◽  
Prostate Cancer Treatment ◽  
Hormone Refractory ◽  
Taxane Chemotherapy

Prostate Cancer: Biology, Incidence, Detection Methods, Treatment Methods, and Vaccines

2020 ◽  
Vol 20 (10) ◽  
pp. 847-854
Author(s):  
Ronald Bartzatt
Keyword(s):  
Prostate Cancer ◽  
Cancer Treatment ◽  
Prostate Specific Antigen ◽  
Cancer Biology ◽  
Early Stage ◽  
Specific Antigen ◽  
Detection Methods ◽  
Hormone Refractory Prostate Cancer ◽  
High Risk Prostate Cancer ◽  
Hormone Refractory

Cancer of the prostate are cancers in which most incidences are slow-growing, and in the U.S., a record of 1.2 million new cases of prostate cancer occurred in 2018. The rates of this type of cancer have been increasing in developing nations. The risk factors for prostate cancer include age, family history, and obesity. It is believed that the rate of prostate cancer is correlated with the Western diet. Various advances in methods of radiotherapy have contributed to lowering morbidity. Therapy for hormone- refractory prostate cancer is making progress, for almost all men with metastases will proceed to hormone-refractory prostate cancer. Smoking cigarettes along with the presence of prostate cancer has been shown to cause a higher risk of mortality in prostate cancer. The serious outcome of incontinence and erectile dysfunction result from the cancer treatment of surgery and radiation, particularly for prostate- specific antigen detected cancers that will not cause morbidity or mortality. Families of patients, as well as patients, are profoundly affected following the diagnosis of prostate cancer. Poor communication between spouses during prostate cancer increases the risk for poor adjustment to prostate cancer. The use of serum prostate-specific antigen to screen for prostate cancer has led to a greater detection, in its early stage, of this cancer. Prostate cancer is the most common malignancy in American men, accounting for more than 29% of all diagnosed cancers and about 13% of all cancer deaths. A shortened course of hormonal therapy with docetaxel following radical prostatectomy (or radiation therapy) for high-risk prostate cancer has been shown to be both safe and feasible. Patients treated with docetaxel-estramustine had a prostate-specific antigen response decline of at least 50%. Cancer vaccines are an immune-based cancer treatment that may provide the promise of a non-toxic but efficacious therapeutic alternative for cancer patients. Further studies will elucidate improved methods of detection and treatment.

In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate

1994 ◽  
Vol 5 (3) ◽  
pp. 336-342 ◽  
Author(s):  
William D Figg ◽  
Ronald G Walls ◽  
Michael R Cooper ◽  
Alain Thibault ◽  
Oliver Sartor ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Antitumor Effect ◽  
Hormone Refractory Prostate Cancer ◽  
Prostate Cancer Cells ◽  
Hormone Refractory

New treatment for advanced and hormone refractory prostate cancer (HRPC) with an oral cholesterol derivative (hydroxysterol 24-ethyl-cholestane- 3β,5α,6α-triol).

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e16531-e16531
Author(s):  
Nabil Habib ◽  
George Hage ◽  
Hamid Elia Daaboul ◽  
Abdo Elias Jabbour ◽  
Hind Zeitouni ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Disease Progression ◽  
Human Cancer ◽  
Symptom Control ◽  
Stage Iv ◽  
Neoplastic Cell ◽  
Phase Cell ◽  
Hormone Refractory Prostate Cancer ◽  
Hormone Refractory

e16531 Background: Hydroxysterols and oxysterols are oxygenated derivatives of cholesterol. They are involved in the regulation of some aspects of neoplastic cell growth and proliferation, as demonstrated in vitro in a variety of human cancer cells including prostate cancer cells.These effects can be dependent on the activation of the oxysterol-binding liver X receptors (LXRs). LNCaP prostate tumor cells stimulated with synthetic LXR agonists showed G1 to S-phase cell cycle arrest through the suppression of Skp2.Prostate cancer is the most frequent cancer in men and most patients become resistant to upfront treatments with hormones. At advanced stages most refractory patients are symptomatic and their life expectancy is limited. (24-ethyl-cholestane- 3β,5α,6α-triol) is a new hydroxysterol developed by us. It is the first oxysterol to be tested in the clinic. It is also one of the safest in this class of compounds. Methods: We have treated with this new drug 14 patients suffering from advanced and hormone-refractory prostate cancer (HRPC). Their median age was 73 (60-88). Seven with a Gleason 7, 5 with a Gleason 8 and 2 with a Gleason 9. Eleven had stage IV disease, Eight with bone metastasis, 4 with advanced loco-regional disease and 2 with visceral metastasis. Ten patients were symptomatic. Four patients had received also 1 line of chemotherapy and 2 others received 2 lines of chemo. Four patients were also previously treated with radiotherapy. Patients received daily 10 mg/Kg of oral (24-ethyl-cholestane- 3β,5α,6α-triol) divided into 3 equal doses, until disease progression. Results: Ten patients experienced either a biological or a radiological partial response (PR), Two patients had a stable disease (NC) and two patients had a disease progression (PD). The median duration of response was 2 years. Patients did not report any side-effect from treatment. Eighty percent of symptomatic patients had a remarkable symptom control. Conclusions: These encouraging results make this new and safe drug a good candidate for further clinical trials either alone or in combination with other drugs in the treatment of HRPC.

scholarly journals Efficacy of Ketoconazole in Hormone Refractory Prostate Cancer Patients

1970 ◽  
Vol 10 (2) ◽  
pp. 52-55
Author(s):  
Parveen Shahida Akhtar ◽  
Riaz Ahmed Chowdhury ◽  
Jafar Md Masud
Keyword(s):  
Prostate Cancer ◽  
Low Cost ◽  
Specific Antigen ◽  
Treatment Protocol ◽  
Retrospective Chart Review ◽  
Hormone Refractory Prostate Cancer ◽  
Cytochrome P450 Enzymes ◽  
Hormone Refractory ◽  
Oncology Centre

Prostate cancer is a common malignancy among males, with the incidence steadily rising over the past years. Patients with small volume metastasis where early chemotherapy is not warranted, in patients with biochemical failure, and in patients who refuse chemotherapy, management remains controversial as there is no universally accepted treatment protocol. Ketoconazole is an antimycotic that inhibits cytochrome P450 enzymes that are required for the synthesis of androgens and other steroids. In addition, in-vitro studies have suggested some direct cytotoxic effects in prostate cancer cell lines. This study aims to describe our experience with ketoconazole treatment for hormone refractory prostate cancer (HRPC) at our centre. Retrospective chart review of HRPC patients given ketoconazole at a private oncology centre in Dhaka from 2005 - 2006 was done. Patients had histologically proven adenocarcinoma of the prostate with rising Prostate Specific Antigen (PSA) despite androgen deprivation therapy (ADT) with orchiectomy, LHRH agonist therapy and antiandrogens. Ketoconazole was given at 200 mg thrice daily. A total of 10 patients with HRPC was treated and evaluated for response and toxicity. Median age was 70 years old.4 (40%) of the 10 patients had a greater than 50% decrease of PSA values. Responses were seen in 66.66% (2/3) of patients with bone-only disease, 20 % (1/5) of patients with bone and soft tissue disease and 1 patient with PSA-only disease. Median duration of response was 6.75 months (range 2-14 months).There were no grade 3 or 4 toxicities. Overall, 5 (50%) patients had toxicity related to ketoconazole. Its good toxicity profile, low cost and ease of administration makes it a viable option to this group of patients specially in our country. Keyword: Prostate cancer, hormone refractory prostate cancer, ketoconazole   doi: 10.3329/jom.v10i2.2814 J MEDICINE 2009; 10 : 52-55

Sign in / Sign up

Export Citation Format

Share Document